4528:TYO
Ono Pharmaceutical Co Ltd
Â¥2,435.50
arrow_upward
+0.87%(+21.00) 1D
Oct 19, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4528...
Open
Â¥2,446
High
Â¥2,450
Low
Â¥2,417
Mkt. cap
1.21T
Avg. vol.
1.51M
Volume
1.35M
Dividend
3.28%
Quarterly dividend
Â¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
15.01
52-wk high
Â¥2,674
52-wk low
Â¥1,764
EPS
Â¥162
Shares outstanding
514.12M
No. of employees
4K
Open
Â¥2,446
High
Â¥2,450
Low
Â¥2,417
Mkt. cap
1.21T
Avg. vol.
1.51M
Volume
1.35M
Dividend
3.28%
Quarterly dividend
Â¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
15.01
52-wk high
Â¥2,674
52-wk low
Â¥1,764
EPS
Â¥162
Shares outstanding
514.12M
No. of employees
4K
News stories
From web sources and news partners
BigGo Finance
·
14 minutes ago
Dow Falls 36 Points for Second Straight Session as Oil Rally Weighs, AI-Related Buying Provides Support
Bloomberg
·
1 hour ago
US Stock Futures Edge Higher After Chipmaker Rally: Markets Wrap
TradingView
·
58 minutes ago
Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line
Investing.com
·
2 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4.21K
Founded1717
HeadquartersOsaka, Osaka, Japan
SectorPharmaceutical industry
Websiteono-pharma.com